Analysts Offer Predictions for SLDB FY2025 Earnings

Solid Biosciences Inc. (NASDAQ:SLDB) – Research analysts at Cantor Fitzgerald issued their FY2025 earnings per share (EPS) estimates for shares of Solid Biosciences in a research report issued on Tuesday, January 21st. Cantor Fitzgerald analyst C. Duncan forecasts that the company will post earnings of ($2.45) per share for the year. The consensus estimate for Solid Biosciences’ current full-year earnings is ($2.84) per share.

SLDB has been the subject of a number of other research reports. Citizens Jmp upgraded Solid Biosciences to a “strong-buy” rating in a report on Tuesday, December 10th. HC Wainwright reissued a “buy” rating and issued a $16.00 target price on shares of Solid Biosciences in a research report on Friday, January 10th. Truist Financial initiated coverage on Solid Biosciences in a research note on Wednesday, January 8th. They issued a “buy” rating and a $16.00 target price on the stock. JMP Securities assumed coverage on shares of Solid Biosciences in a research note on Tuesday, December 10th. They set an “outperform” rating and a $15.00 price target for the company. Finally, Wedbush started coverage on shares of Solid Biosciences in a research report on Friday, December 13th. They issued an “outperform” rating and a $16.00 price objective on the stock. Nine analysts have rated the stock with a buy rating and four have assigned a strong buy rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Buy” and a consensus target price of $15.30.

Solid Biosciences Stock Down 3.8 %

Shares of NASDAQ:SLDB opened at $3.00 on Wednesday. The firm has a market cap of $119.88 million, a price-to-earnings ratio of -0.99 and a beta of 2.05. Solid Biosciences has a 12 month low of $2.97 and a 12 month high of $15.05. The company’s fifty day simple moving average is $4.47 and its 200 day simple moving average is $6.45.

Solid Biosciences (NASDAQ:SLDB) last announced its earnings results on Wednesday, November 6th. The company reported ($0.79) EPS for the quarter, missing the consensus estimate of ($0.67) by ($0.12).

Insider Buying and Selling at Solid Biosciences

In related news, COO David T. Howton sold 5,072 shares of the business’s stock in a transaction that occurred on Tuesday, December 3rd. The stock was sold at an average price of $5.60, for a total transaction of $28,403.20. Following the transaction, the chief operating officer now directly owns 15,663 shares of the company’s stock, valued at approximately $87,712.80. The trade was a 24.46 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Alexander Cumbo sold 11,114 shares of the stock in a transaction on Tuesday, December 3rd. The shares were sold at an average price of $5.60, for a total value of $62,238.40. Following the completion of the sale, the chief executive officer now owns 38,484 shares in the company, valued at approximately $215,510.40. This trade represents a 22.41 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 25,925 shares of company stock worth $136,853 over the last quarter. 13.63% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Solid Biosciences

Several institutional investors and hedge funds have recently modified their holdings of SLDB. Dimensional Fund Advisors LP boosted its holdings in shares of Solid Biosciences by 8.1% during the 2nd quarter. Dimensional Fund Advisors LP now owns 70,827 shares of the company’s stock worth $402,000 after buying an additional 5,287 shares during the period. MetLife Investment Management LLC lifted its position in Solid Biosciences by 129.1% during the third quarter. MetLife Investment Management LLC now owns 13,699 shares of the company’s stock worth $95,000 after acquiring an additional 7,719 shares during the last quarter. American Century Companies Inc. boosted its holdings in shares of Solid Biosciences by 39.9% during the second quarter. American Century Companies Inc. now owns 34,557 shares of the company’s stock worth $196,000 after acquiring an additional 9,853 shares during the period. The Manufacturers Life Insurance Company bought a new stake in shares of Solid Biosciences during the third quarter worth approximately $71,000. Finally, Point72 DIFC Ltd acquired a new position in shares of Solid Biosciences in the second quarter valued at approximately $58,000. 81.46% of the stock is currently owned by institutional investors and hedge funds.

About Solid Biosciences

Solid Biosciences Inc, a life science company, develops therapies for neuromuscular and cardiac diseases in the United States. The company's lead product candidate is SGT-003, a gene transfer candidate for the treatment of Duchenne muscular dystrophy; and SGT-501 to treat Catecholaminergic polymorphic ventricular tachycardia.